HUTCHMED (NASDAQ:HCM) Stock Price Up 6.9% – What’s Next?

HUTCHMED (China) Limited (NASDAQ:HCM)’s stock price was up 6.9% during trading on Monday . The stock traded as high as $14.75 and last traded at $14.67. Approximately 41,471 shares traded hands during trading, a decline of 62% from the average daily volume of 107,935 shares. The stock had previously closed at $13.72.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a research note on Friday, March 21st.

HUTCHMED Price Performance

The company has a fifty day moving average price of $14.75 and a two-hundred day moving average price of $16.14. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07.

Institutional Investors Weigh In On HUTCHMED

Hedge funds have recently made changes to their positions in the business. State Street Corp lifted its position in HUTCHMED by 0.9% during the 3rd quarter. State Street Corp now owns 349,524 shares of the company’s stock worth $6,826,000 after acquiring an additional 3,078 shares during the period. Jane Street Group LLC increased its stake in HUTCHMED by 362.2% in the 3rd quarter. Jane Street Group LLC now owns 62,997 shares of the company’s stock valued at $1,305,000 after buying an additional 49,366 shares during the period. Public Employees Retirement System of Ohio purchased a new position in HUTCHMED during the 3rd quarter worth $35,000. Crossmark Global Holdings Inc. boosted its holdings in shares of HUTCHMED by 10.7% in the fourth quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company’s stock valued at $268,000 after acquiring an additional 1,799 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in HUTCHMED by 99.9% during the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company’s stock worth $102,000 after purchasing an additional 3,532 shares in the last quarter. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.